Zurcher Kantonalbank Zurich Cantonalbank Buys 17,822 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 3.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 585,686 shares of the company’s stock after buying an additional 17,822 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank owned 0.05% of Teva Pharmaceutical Industries worth $18,279,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of TEVA. AQR Capital Management LLC increased its position in shares of Teva Pharmaceutical Industries by 24.6% during the first quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock valued at $368,000 after buying an additional 4,732 shares during the period. Focus Partners Wealth increased its position in shares of Teva Pharmaceutical Industries by 4.5% during the first quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock valued at $616,000 after buying an additional 1,739 shares during the period. Franklin Resources Inc. bought a new stake in shares of Teva Pharmaceutical Industries during the second quarter valued at about $255,000. Flow Traders U.S. LLC bought a new stake in shares of Teva Pharmaceutical Industries during the second quarter valued at about $238,000. Finally, Cerity Partners LLC increased its position in shares of Teva Pharmaceutical Industries by 2.9% during the second quarter. Cerity Partners LLC now owns 45,837 shares of the company’s stock valued at $768,000 after buying an additional 1,291 shares during the period. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Stock Down 0.2%

Shares of NYSE TEVA opened at $31.23 on Thursday. Teva Pharmaceutical Industries Ltd. has a one year low of $14.16 and a one year high of $37.35. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.04 and a quick ratio of 0.80. The firm’s 50 day simple moving average is $31.35 and its two-hundred day simple moving average is $28.87. The stock has a market capitalization of $35.90 billion, a P/E ratio of 26.02, a PEG ratio of 2.74 and a beta of 0.76.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.31. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The firm had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.36 billion. During the same quarter last year, the business earned $0.71 earnings per share. The business’s revenue was up 11.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.62 EPS for the current fiscal year.

Insider Transactions at Teva Pharmaceutical Industries

In other news, EVP Richard Daniell sold 17,295 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total value of $547,732.65. Following the transaction, the executive vice president owned 85,755 shares in the company, valued at approximately $2,715,860.85. This trade represents a 16.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Eliyahu Sharon Kalif sold 345,810 shares of the firm’s stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $33.64, for a total transaction of $11,633,048.40. Following the completion of the transaction, the executive vice president owned 57,478 shares in the company, valued at $1,933,559.92. This represents a 85.75% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 920,901 shares of company stock valued at $30,056,789. 0.54% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on TEVA shares. The Goldman Sachs Group raised their target price on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 31st. Truist Financial raised their target price on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Monday. Finally, Jefferies Financial Group raised their target price on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of “Moderate Buy” and an average price target of $38.78.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.